Dendritic cell therapy shows success in lung cancer with metastases.

While conventional oncology often reaches its limits in metastatic lung cancer, modern immunotherapy offers new hope: dendritic cell therapy (DZT) uses the body's own immune intelligence to specifically recognize and combat tumour cells.

Functional principle of dendritic cell therapy

Dendritic cells are considered the "generals" of the immune system.
They present the characteristic antigens of tumour cells to the immune system and thereby activate specific killer cells (T cells), which recognize and destroy cancer cells.

During therapy, immune cells are isolated from the patient's blood, differentiated into highly active dendritic cells in the laboratory and then loaded with the patient's own tumor antigens.
These "trained" cells are returned to the patient in several cycles - similar to a vaccination against the patient's own tumor.

Example of a successful treatment

A 63-year-old patient from Germany, who was diagnosed with stage IV non-small cell lung cancer (NSCLC) with liver and bone metastases in 2023, opted for complementary dendritic cell therapy in combination with "ImmuSeroForte" - an immunomodulatory defect drug to strengthen the cellular immune response - after several conventional lines of therapy (chemotherapy and immune checkpoint inhibitors).

After a series of four application cycles over a period of six months, the PET/CT:

Significant regression of the liver metastases,

stabilization of the pulmonary lesion,

as well as a significant increase in cellular immune activity (CD8+, IFN-g).

The patient reported improved exercise tolerance, appetite and quality of life, with only minimal side effects (slight fever, fatigue after injection).

Immunological cancer therapy as an individual option

The results show that patient-specific immune activation through dendritic cell therapy can also achieve clinically relevant effects in late stages of the disease - especially when combined with stabilizing measures such as micronutrient therapy, ozone-oxygen therapy or hyperthermia.

"Dendritic cell therapy is not a substitute, but a biological supplement to existing therapy concepts - with the aim of bringing the immune system back into active dialog with the tumor," explains Andreas Rach, founder of IMMUMEDIC Limited, an international network for patient-specific cell therapies.

Conclusion

Immuno-oncology is developing rapidly - and dendritic cell therapy shows that personalized treatments can also lead to stabilization, remission and improved quality of life in metastatic tumors.
Over 200 clinical trials are currently underway worldwide to further investigate the value of this form of therapy.

Note

Dendritic cell therapy is a patient-specific form of treatment based on the body's own immune cells.
It does not replace conventional medical therapy, but can improve immune stability and therapy response rates as a complementary approach.

IMMUMEDIC Limited
Bessemerstrasse 51 1.OG
12103 Berlin
Germany

https://www.dendritische-zelltherapie-deutschland.com/

Andreas Rach
+49 16091942558

immumedic@gmail.com

IMMUMEDIC Limited is an internationally active company in the field of medical logistics and innovative cancer therapies. Our focus is on the organization, coordination and delivery of advanced immunotherapies, in particular dendritic cell therapy and complementary treatment approaches such as oncolytic viruses and immune boosting programs.

We work closely with specialized clinics, practices and research institutions in Europe and offer patients access to individually tailored, scientifically sound therapy concepts. We not only provide medical and logistical care, but also comprehensive advice to give patients and their families guidance in a challenging life situation.

With a network of experienced doctors, therapists and partner laboratories, we enable a smooth process - from diagnosis analysis and therapy planning to the implementation of treatments. Our aim is to give patients hope, quality of life and new perspectives in the fight against cancer.

IMMUMEDIC Limited - your partner for innovative immunotherapies and holistic healthcare solutions.

This release was published on openPR.